#United States #Rockville #REGENXBIO #RGX-202 #Phase III

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. has recently unveiled its financial performance and operational milestones for the first quarter of 2026, showcasing significant advancements in their gene therapy projects. Notably, the company announced successful topline results from the pivotal Phase III AFFINITY DUCHENNE trial concerning their RGX-202 gene therapy.

Positive Developments in RGX-202 Research

The results from the AFFINITY DUCHENNE trial were promising. REGENXBIO reported a high statistical significance for the primary endpoint, noting that 93% of participants expressed RGX-202 microdystrophin at levels exceeding 10%. This is a significant achievement, as it supports the therapy's potential effectiveness in treating Duchenne muscular dystrophy—an area with pressing unmet medical needs.

The RGX-202 treatment is uniquely designed to provide a microdystrophin that closely mimics the natural dystrophin protein, while also incorporating innovative techniques such as a proactive immune suppression regimen and advanced manufacturing processes to ensure high product purity. These attributes position RGX-202 as a potentially best-in-class therapy, aimed at improving muscle function and durability in patients aged one and older.

Ongoing Clinical Trials and Future Prospects

Enrollment in the confirmatory trials is on track, with more than 20 additional participants added to the existing study cohort, bringing the participant number to 60. The company aims to complete dosing by mid-2026. The continued advancement of RGX-202 sets the stage for a potential submission for accelerated approval in 2027, further solidifying REGENXBIO's commitment to addressing rare diseases.

Financial Performance Overview

In terms of financial results, REGENXBIO reported cash, cash equivalents, and marketable securities amounting to $150.5 million as of March 31, 2026. This figure reflects a decline from $240.9 million reported the previous quarter due to operational expenditures, including a substantial one-time payment related to a previously disclosed settlement with GlaxoSmithKline.

Total revenues for the quarter stood at $6.4 million, a sharp drop compared to $89.0 million in the same period last year. The decrease is largely attributed to the absence of upfront licensing revenue from collaborations that were realized in the first quarter of 2025. Additionally, a reduction in royalty revenues from ZOLGENSMA exacerbated the decline.

Research and development expenses totaled $57.3 million, reflecting increased costs associated with clinical trial activities for RGX-202. Likewise, general and administrative expenditures rose slightly to $21.3 million. This resulted in a net loss of $90.1 million, translating to a loss per share of $1.72, in contrast to a net profit of $6.1 million during the same quarter the previous year.

Looking Ahead

REGENXBIO is not just focusing on RGX-202; they are also making strides with other therapies. Surabgene lomparvovec (sura-vec), developed in collaboration with AbbVie, is positioned to address wet age-related macular degeneration and diabetic retinopathy, with an anticipated sharing of pivotal trial data expected later this year. The company remains optimistic about creating impactful breakthroughs in the gene therapy landscape.

As REGENXBIO moves deeper into 2026, the industry will be closely monitoring their progress in clinical trials and the financial implications of their innovative therapies. The upcoming conference call promises to shed further light on the topline data for RGX-202 and the broader implications of their Q1 results, making it an important event for investors and stakeholders in the biotechnology sector.

In summary, with a robust pipeline and increasing clinical validations, REGENXBIO is on a path that could redefine treatment frameworks for various genetic disorders, demonstrating their commitment to advancing healthcare through gene therapy.